Abstract
Adrenomyeloneuropathy (AMN) is the most common manifestation of X-linked adrenoleukodystrophy (X-ALD), a rare neurodegenerative disease caused by mutations in ABCD1, featuring progressive myeloneuropathy, spastic paraparesis, sensory ataxia, loss of mobility, incontinence, and sexual dysfunction. Presentation, onset and clinical manifestations vary between men and women. This study sought to quantify for the first time the impact of AMN on healthcare costs in commercially insured adults, both male and female, in the US.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
